Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Opexa Therapeutics, Inc. (“Opexa” or the “Company”) (NasdaqCM: OPXA) for potential breaches of fiduciary duties in connection with their conduct in seeking shareholders’ approval for the Company’s Amended and Restated 2010 Stock Incentive Plan. Specifically, in the Proxy Statement filed by the Company with the Securities and Exchange Commission on October 3, 2013, the Board of Directors recommends that Opexa’s shareholders vote to approve an amendment to the Company’s Amended and Restated 2010 Stock Incentive Plan to increase the number of shares available for issuance thereunder by 3,000,000 shares. The issuance of the additional shares could have a substantial dilutive effect on the shares of Opexa common stock. Request more information now by clicking here: www.faruqilaw.com/OPXA. There is no cost or obligation to you.Faruqi & Faruqi, LLP is a national law firm which represents investors and individuals in class action litigation. The firm is focused on providing exemplary legal services in complex litigation in the areas of securities, shareholder, antitrust and consumer litigation, throughout all phases of litigation. The firm has an experienced trial team which has achieved significant victories on behalf of the firm’s clients. If you own common stock in Opexa and wish to obtain additional information and protect your investments free of charge, please visit us at www.faruqilaw.com/OPXA or contact Juan E. Monteverde, Esq. either via e-mail at firstname.lastname@example.org or by telephone at (877) 247-4292 or (212) 983-9330. Attorney Advertising. (C) 2013 Faruqi & Faruqi, LLP. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We are happy to discuss your particular case.